AbbVie Inc. (ABBV)

65.97
1.55 2.30
NYSE : Health Technology
Prev Close 67.52
Open 67.28
Day Low/High 65.48 / 67.79
52 Wk Low/High 62.66 / 98.70
Volume 8.80M
Avg Volume 10.25M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 99.86B
EPS 3.70
P/E Ratio 24.04
Div & Yield 4.28 (6.28%)
Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks look past the worst gun shooting in U.S. history on Monday, Oct. 2, to trade at new records.

Stocks at Records as U.S. Manufacturing Conditions Improve

Stocks at Records as U.S. Manufacturing Conditions Improve

Stocks begin the new month and quarter with gains on Monday, Oct. 2, as manufacturing conditions hold in expansion territory for another month.

AbbVie And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate A Therapeutic Regimen In Advanced Solid Tumors

AbbVie And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate A Therapeutic Regimen In Advanced Solid Tumors

AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and...

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Jim Cramer is bullish on Arconic, Idexx Laboratories, AbbVie. He's bearish on Fitbit, Qualcomm and Walgreens.

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Don't be distracted and start buying high and selling low, says Jim Cramer. A good example? Don't trade Apple, own it.

AbbVie Is Likely to Correct: Book Some Profits

AbbVie Is Likely to Correct: Book Some Profits

ABBV has gone 'vertical' on the daily chart.

AbbVie Becomes #164 Most Shorted S&P 500 Component, Replacing Moody's Corp.

AbbVie Becomes #164 Most Shorted S&P 500 Component, Replacing Moody's Corp.

The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Hedge fund managers are out with their top stock picks. So who made the list?

What SOX Says About Oversold Rallies

Expect the market to come down again.

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Evercore ISI analyst Josh Schimmer is bullish on biotech.

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Jim Cramer is bullish on EPR Properties, Activision Blizzard, AbbVie, and ON Semiconductor.

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

Cramer says this is not the end of the selloff. That's why you should be mentally and financially ready for panic moves -- and opportunities.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

U.S. stock futures fall as earnings from Amazon.com disappoint.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

AbbVie Reaches All-Time Highs

AbbVie Reaches All-Time Highs

Today's breakout could carry the stock sharply higher.

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Remarkable data was released from Vertex's triple regiment combination trials.

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

Tech companies aren't the only ones seeing their shares rise this year.

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in Healthcare

What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in Healthcare

Players include Apple, Google, Microsoft and Samsung.

Samsung Could Sell More Drugs

Samsung Could Sell More Drugs

Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher

AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher

AbbVie's June rally has now driven shares past the 2016 high.

TheStreet Quant Rating: B- (Buy)